Regulatory Rapporteur - March 2025 | Regulatory Rapporteur

Regulatory Rapporteur – March 2025

Data and AI: Readiness, research and real-world impact

Organising high quality research and development data for success

AI adoption readiness: Current status and trends in regulatory organisations

Artificial intelligence and post-market surveillance

Using data to drive regulatory performance

Immunological considerations in the development of novel vaccines

The EU’s Health Technology Assessment Regulation: Overview and considerations for regulatory teams

March 2025 – Contents
Data and AI: Readiness, research and real-world impact
Organising high quality research and development data for success
AI adoption readiness: Current status and trends in regulatory organisations
Artificial intelligence and post-market surveillance
Using data to drive regulatory performance
Immunological considerations in the development of novel vaccines
The EU’s Health Technology Assessment Regulation: Overview and considerations for regulatory teams

Industry News

Rui Santos Ivo elected as new Chair of the EMA Management Board
Rui Santos Ivo has been elected as the new Chair of the European Medicines Agency (EMA) Management Board. Mr Santos Ivo takes over from Lorraine Nolan, who completed her tenure on 21 March 2025.
UK life science sector calls for more diverse workforce skills to secure future growth
To deliver cutting-edge treatments and revolutionise patient outcomes, the future life sciences sector workforce must be equipped with skills ranging from advanced scientific expertise, digital proficiency and AI-driven problem solving, according to a newly published report.
MHRA appoints new Chief Executive Officer
Lawrence Tallon has been appointed the new Chief Executive Officer at the Medicines and Healthcare products Regulatory Agency (MHRA) and will begin the role on 1 April 2025.

More news

Pharmacies told to follow GPhC guidance on prescription-only weight-loss medicine

Online pharmacies in England, Scotland and Wales are required to follow updated guidance from the General Pharmaceutical Council (GPhC), after concerns that prescription-only medicines (POM) for weight loss are being inappropriately supplied.